LobbyingTaurx Pharmaceuticals lobbying by quarter
Taurx Pharmaceuticals's latest lobbying report covers Q1 2024, at under $5,000. Its first report covers Q1 2023; the issues it reports most are Health Issues.
Taurx Pharmaceuticals
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q1 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2023 | $70K | 1 |
| Q2 2023 | $60K | 1 |
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$130K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| King & Spalding | $130K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SCOTT DZIENGELSKI | Rep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst.(2013-2015),Leg. Asst. (2012-2013), Leg. Corr. (2011-2012),Staff Asst. (2010-2011);Energy and Commerce Committee:Staff (2015-2017) | Q2 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/04/19for Q1 2024 | King & Spalding | Under $5,000 |
| 24/01/15for Q4 2023 | King & Spalding | Under $5,000 |
| 23/10/16for Q3 2023 | King & Spalding | Under $5,000 |
| 23/07/11for Q2 2023 | King & Spalding | $60K |
| 23/04/18for Q1 2023 | King & Spalding | $70K |
| 23/02/08for Q1 2023 | King & Spalding | Under $5,000 |